Germany · Delayed Price · Currency is EUR Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of EUR 6.77 billion. The enterprise value is 18.31 billion.
| Market Cap | 6.77B |
| Enterprise Value | 18.31B |
Important Dates
The next estimated earnings date is Friday, October 31, 2025.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
| Current Share Class | 1.34B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.48% |
| Shares Change (QoQ) | +0.98% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 27.63% |
| Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 8.15 and the forward PE ratio is 7.15.
| PE Ratio | 8.15 |
| Forward PE | 7.15 |
| PS Ratio | 0.10 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 22.04 |
| EV / Sales | 0.26 |
| EV / EBITDA | 6.41 |
| EV / EBIT | 7.95 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 4.17 |
| Debt / FCF | n/a |
| Interest Coverage | 6.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 645,146 |
| Profits Per Employee | 7,679 |
| Employee Count | 108,217 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Sinopharm Group has paid 436.60 million in taxes.
| Income Tax | 436.60M |
| Effective Tax Rate | 26.12% |
Stock Price Statistics
The stock price has decreased by -9.63% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -9.63% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.15 |
| Relative Strength Index (RSI) | 65.99 |
| Average Volume (20 Days) | 2,403 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of EUR 69.82 billion and earned 831.00 million in profits. Earnings per share was 1.48.
| Revenue | 69.82B |
| Gross Profit | 5.30B |
| Operating Income | 2.13B |
| Pretax Income | 1.67B |
| Net Income | 831.00M |
| EBITDA | 2.40B |
| EBIT | 2.13B |
| Earnings Per Share (EPS) | 1.48 |
Balance Sheet
The company has 5.65 billion in cash and 11.17 billion in debt, giving a net cash position of -5.52 billion.
| Cash & Cash Equivalents | 5.65B |
| Total Debt | 11.17B |
| Net Cash | -5.52B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.50B |
| Book Value Per Share | 3.08 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 7.59%, with operating and profit margins of 3.05% and 1.19%.
| Gross Margin | 7.59% |
| Operating Margin | 3.05% |
| Pretax Margin | 2.39% |
| Profit Margin | 1.19% |
| EBITDA Margin | 3.43% |
| EBIT Margin | 3.05% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 3.81%.
| Dividend Per Share | 0.08 |
| Dividend Yield | 3.81% |
| Dividend Growth (YoY) | -28.81% |
| Years of Dividend Growth | 4 |
| Payout Ratio | n/a |
| Buyback Yield | 0.48% |
| Shareholder Yield | 4.28% |
| Earnings Yield | 12.27% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |